Last reviewed 2026-04-22 · How we verify

Oral lumbrokinase DLBS1033

Lumbrokinase is a fibrinolytic enzyme derived from earthworm that breaks down fibrin clots and improves blood flow.

Lumbrokinase is a fibrinolytic enzyme derived from earthworm that breaks down fibrin clots and improves blood flow. Used for Thromboembolism and blood stasis-related conditions, Diabetic angiopathy, Cerebrovascular disorders.

At a glance

Mechanism of action

Lumbrokinase is a serine protease extracted from earthworm (Lumbricus rubellus) that directly degrades fibrin in blood clots and enhances fibrinolysis. It works through multiple pathways including direct fibrin degradation and activation of endogenous fibrinolytic systems, thereby reducing blood viscosity and improving microcirculation. This mechanism makes it useful for thromboembolic and microcirculatory disorders.

Approved indications

• Thromboembolism and blood stasis-related conditions
• Diabetic angiopathy
• Cerebrovascular disorders

Common side effects

• Bleeding or hemorrhage
• Gastrointestinal upset
• Allergic reactions

Key clinical trials

• The Effect of Oral DLBS1033 in Patients With Diabetic Polyneuropathy (PHASE2, PHASE3)
• Oral DLBS1033 as Adjunctive Therapy in Acute Ischemic Stroke: Impact on Inflammatory Biomarkers and Outcomes (PHASE4)
• Comparing Oral Lumbrokinase DLBS1033 and Betahistine Mesylate in Benign Paroxysmal Positional Vertigo (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Oral lumbrokinase DLBS1033 CI brief — competitive landscape report
• Oral lumbrokinase DLBS1033 updates RSS · CI watch RSS
• Universitas Sebelas Maret portfolio CI